Robert Orlowski, MDMerck & Co. Inc., Kenilworth, NJ
Characterization and Management of Adverse Reactions in Patients with Endometrial Carcinoma Receiving Lenvatinib plus Pembrolizumab (Study 111/KEYNOTE-146): Nurse Roles in Patient Education and Adverse-Reaction Management
Krysten Soldan, RN, Carolyn Johns, NP, Matthew H. Taylor, MD, Kathryn Gillis, PharmD, Robert Orlowski, MD, Min Ren, Vicky Makker
November 13, 2020 | November 2020 Vol 11, No 11
Lenvatinib plus pembrolizumab demonstrated promising antitumor activity in endometrial carcinoma (EC) in a phase 1b/2 clinical trial (Study 111/KEYNOTE-146).
Last modified: November 13, 2020